Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
McKesson
Harvard Business School
Federal Trade Commission
US Department of Justice
Mallinckrodt
Teva
US Army
Express Scripts

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,592,339

« Back to Dashboard

Summary for Patent: 7,592,339
Title:Substituted oxazolidinones and their use in the field of blood coagulation
Abstract: The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR00001## processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Inventor(s): Straub; Alexander (Wuppertal, DE), Lampe; Thomas (Wuppertal, DE), Pohlmann; Jens (Wuppertal, DE), Rohrig; Susanne (Essen, DE), Perzborn; Elisabeth (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Pernerstorfer; Joseph (Wuppertal, DE)
Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE)
Application Number:11/460,529
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,592,339

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETON OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS ➤ Try a Free Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) ➤ Try a Free Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Try a Free Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,592,339

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,585,860 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Try a Free Trial
8,129,378 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Try a Free Trial
8,530,505 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Try a Free Trial
7,157,456 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,592,339

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 200422299 ➤ Try a Free Trial
Taiwan I226330 ➤ Try a Free Trial
Turkey 200401314 ➤ Try a Free Trial
Turkey 200201636 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Fuji
Daiichi Sankyo
Queensland Health
US Department of Justice
Chubb
Teva
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.